Search Result

Pathways Recommended:	Immunology/Inflammation

Results for "

soft tissue inflammation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (2) Antibiotic (4) Apoptosis (4) Autophagy (2) Bacterial (6) Calcium Channel (2) COX (4) Drug Derivative (1) Interleukin Related (1) Isotope-Labeled Compounds (3) Mineralocorticoid Receptor (2) Reactive Oxygen Species (ROS) (1) Reference Standards (3) TOPK (4)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Endocrinology (1) Infection (6) Inflammation/Immunology (12) Metabolic Disease (2) Neurological Disease (4)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Targets Recommended: Tissue Factor Pathway Inhibitor (TFPI) MALT1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0561

Spironolactone Maximum Cited Publications 7 Publications Verification SC9420	Mineralocorticoid Receptor Androgen Receptor Autophagy Calcium Channel	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC₅₀=24 nM) and androgen receptor (IC₅₀=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca ²⁺ channels to exert antihypertensive effects .

HY-B1156

Cephradine 5 Publications Verification Cefradine; SQ-11436	Bacterial Antibiotic TOPK	Infection Inflammation/Immunology
Cephradine (Cefradine) is a broad-spectrum and orally active cephalosporin. Cephradine is active against both gram-positive and gram-negative pathogens. Cephradine is effective in eradicating most penicillinase-producing organisms. Cephradine has been used in the research of genitourinary, gastrointestinal and respiratory tract infections, and in infections of the skin and soft tissues. Cephradine blocks solar-ultraviolet induced skin inflammation through direct inhibition of TOPK .

HY-128449

Cephradine monohydrate 5 Publications Verification Cefradine monohydrate	Bacterial Antibiotic TOPK	Infection Inflammation/Immunology
Cephradine (Cefradine) monohydrate is a broad-spectrum and orally active cephalosporin. Cephradine monohydrate is active against both grampositive and gram-negative pathogens and effective in eradicating most penicillinase-producing organisms known to be resistant to penicillin G, penicillin V, and ampicillin. Cephradine monohydrate has been used in the research of genitourinary, gastrointestinal and respiratory tract infections, and in infections of the skin and soft tissues. Cephradine monohydrate blocks solar-ultraviolet induced skin inflammation through direct inhibition of TOPK .

HY-P1116

PBP10 1 Publications Verification	Bacterial Reactive Oxygen Species (ROS) Interleukin Related	Infection Inflammation/Immunology
PBP10 is a decapeptide. PBP10 selectively binds to lipoteichoic acid (LTA), lipopolysaccharide (LPS) and phosphatidylinositol-4,5-bisphosphate (PIP₂). PBP10 penetrates cell membranes and possesses bactericidal, anti-inflammatory, cell motility-inhibiting and actin assembly-regulating activities. PBP10 is applicable to relevant research on bacterial infections, microbe-induced inflammation, skin and soft tissue infections, as well as sepsis .

HY-17488

Morniflumate UP 164	Others	Inflammation/Immunology
Morniflumate (UP 164) is an orally active nonsteroidal anti-inflammatory agent. Morniflumate can be used in the study of inflammatory diseases such as osteoarthritis, painful musculoskeletal disorders and soft tissue inflammation.

HY-P1116A

PBP10 TFA 1 Publications Verification	Bacterial	Infection Inflammation/Immunology
PBP10 TFA is a decapeptide. PBP10 TFA selectively binds to lipoteichoic acid (LTA), lipopolysaccharide (LPS) and phosphatidylinositol-4,5-bisphosphate (PIP₂). PBP10 TFA penetrates cell membranes and possesses bactericidal, anti-inflammatory, cell motility-inhibiting and actin assembly-regulating activities. PBP10 TFA is applicable to relevant research on bacterial infections, microbe-induced inflammation, skin and soft tissue infections, as well as sepsis .

HY-17509

Deracoxib 1 Publications Verification SC 046; SC 46; SC 59046	COX Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Deracoxib (SC 046; SC 59046), an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas .

HY-17509S

Deracoxib-d3 SC 046-d₃; SC 46-d₃; SC 59046-d₃	Isotope-Labeled Compounds COX Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Deracoxib-d₃ (SC 046-d₃; SC 59046-d₃) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

HY-B0561S4

Spironolactone-d6-1	Isotope-Labeled Compounds Mineralocorticoid Receptor Androgen Receptor Autophagy Calcium Channel	Cardiovascular Disease Metabolic Disease Cancer
Spironolactone-d₆-1 is the deuterium labeled Spironolactone (HY-B0561). Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC₅₀=24 nM) and androgen receptor (IC₅₀=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca ²⁺ channels to exert antihypertensive effects .

HY-B1156A

Cephradine sodium Cefradine sodium; SQ-11436 sodium	Bacterial Antibiotic TOPK	Infection Inflammation/Immunology
Cephradine sodium is a broad-spectrum and orally active cephalosporin. Cephradine sodium is active against both gram-positive and gram-negative pathogens. Cephradine sodium is effective in eradicating most penicillinase-producing organisms. Cephradine sodium has been used in the research of genitourinary, gastrointestinal and respiratory tract infections, and in infections of the skin and soft tissues. Cephradine sodium blocks solar-ultraviolet induced skin inflammation through direct inhibition of TOPK .

HY-B1156R

Cephradine (Standard) Cefradine (Standard); SQ-11436 (Standard)	Reference Standards Bacterial Antibiotic TOPK	Infection Inflammation/Immunology
Cephradine (Standard) is the analytical standard of Cephradine. This product is intended for research and analytical applications. Cephradine (Cefradine) is a broad-spectrum and orally active cephalosporin. Cephradine is active against both gram-positive and gram-negative pathogens. Cephradine is effective in eradicating most penicillinase-producing organisms. Cephradine has been used in the research of genitourinary, gastrointestinal and respiratory tract infections, and in infections of the skin and soft tissues. Cephradine blocks solar-ultraviolet induced skin inflammation through direct inhibition of TOPK .

HY-17488R

Morniflumate (Standard) UP 164 (Standard)	Drug Derivative Reference Standards	Inflammation/Immunology
Morniflumate (Standard) is the analytical standard of Morniflumate. This product is intended for research and analytical applications. Morniflumate (UP 164) is an orally active nonsteroidal anti-inflammatory agent, the β-morpholinoethyl ester of Niflumic acid (HY-B0493). Morniflumate can be used in the study of inflammatory diseases such as osteoarthritis, painful musculoskeletal disorders and soft tissue inflammation.

HY-17509R

Deracoxib (Standard) SC 046 (Standard); SC 46 (Standard); SC 59046 (Standard)	Reference Standards COX Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Deracoxib (SC 046; SC 59046) (Standard) is the analytical standard of Deracoxib (HY-17509). This product is intended for research and analytical applications. Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas

HY-W703540

Deracoxib-d4 SC 046-d₄; SC 46-d₄; SC 59046-d₄	Isotope-Labeled Compounds Apoptosis COX	Neurological Disease Inflammation/Immunology Cancer
Deracoxib-d₄ (SC 046-d₄; SC 59046--d₄) is deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

Cat. No.	Product Name	Target	Research Area

HY-P1116

PBP10 1 Publications Verification	Bacterial Reactive Oxygen Species (ROS) Interleukin Related	Infection Inflammation/Immunology
PBP10 is a decapeptide. PBP10 selectively binds to lipoteichoic acid (LTA), lipopolysaccharide (LPS) and phosphatidylinositol-4,5-bisphosphate (PIP₂). PBP10 penetrates cell membranes and possesses bactericidal, anti-inflammatory, cell motility-inhibiting and actin assembly-regulating activities. PBP10 is applicable to relevant research on bacterial infections, microbe-induced inflammation, skin and soft tissue infections, as well as sepsis .

HY-P1116A

PBP10 TFA 1 Publications Verification	Bacterial	Infection Inflammation/Immunology
PBP10 TFA is a decapeptide. PBP10 TFA selectively binds to lipoteichoic acid (LTA), lipopolysaccharide (LPS) and phosphatidylinositol-4,5-bisphosphate (PIP₂). PBP10 TFA penetrates cell membranes and possesses bactericidal, anti-inflammatory, cell motility-inhibiting and actin assembly-regulating activities. PBP10 TFA is applicable to relevant research on bacterial infections, microbe-induced inflammation, skin and soft tissue infections, as well as sepsis .

Cat. No.	Product Name	Chemical Structure

HY-17509S

Deracoxib-d3
Deracoxib-d₃ (SC 046-d₃; SC 59046-d₃) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

Deracoxib-d3

Deracoxib-d₃ (SC 046-d₃; SC 59046-d₃) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

HY-B0561S4

Spironolactone-d6-1
Spironolactone-d₆-1 is the deuterium labeled Spironolactone (HY-B0561). Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC₅₀=24 nM) and androgen receptor (IC₅₀=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca ²⁺ channels to exert antihypertensive effects .

Spironolactone-d6-1

Spironolactone-d₆-1 is the deuterium labeled Spironolactone (HY-B0561). Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC₅₀=24 nM) and androgen receptor (IC₅₀=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca ²⁺ channels to exert antihypertensive effects .

HY-W703540

Deracoxib-d4
Deracoxib-d₄ (SC 046-d₄; SC 59046--d₄) is deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

Deracoxib-d4

Deracoxib-d₄ (SC 046-d₄; SC 59046--d₄) is deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.